Skip to Main Content

Paper Details

A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.
Clin Cancer Res
167
2019
AR, Alisertib, Aurora, Aurora Kinase A, Aurora-A, BRCA2, Castration-resistant and Neuroendocrine Prostate Cancer, N, N-myc, NEPC, Neuroendocrine prostate cancer, PATIENTS, PSA, PTEN, Patient, Patients, RB1, RNA, TP53, advanced prostate cancer, alisertib, androgen, androgen receptor, liver metastases, men, metastatic prostate cancer, myc, patient, patients, prostate cancer, small-, small-cell neuroendocrine morphology, tumor, tumors, visceral metastases
Author NameAffiliation
Himisha Beltran
Himisha BeltranEnglander Institute for Precision Medicine, New York Presbyterian Hospital- Weill Cornell Medicine
Himisha Beltran
Himisha BeltranEnglander Institute for Precision Medicine, New York Presbyterian Hospital- Weill Cornell Medicine
Clara Oromendia
Bruce MontgomeryUniversity of Washington
Juan Miguel MosqueraEnglander Institute for Precision Medicine, New York Presbyterian Hospital- Weill Cornell Medicine
Juan Miguel Mosquera
Juan Miguel MosqueraEnglander Institute for Precision Medicine, New York Presbyterian Hospital- Weill Cornell Medicine
Juan Miguel Mosquera
Verena SailerEnglander Institute for Precision Medicine, New York Presbyterian Hospital- Weill Cornell Medicine
Rohan BarejaEnglander Institute for Precision Medicine, New York Presbyterian Hospital- Weill Cornell Medicine
Alessandro RomanelUniversity of Trento
Alessandro RomanelUniversity of Trento
Andrea SbonerEnglander Institute for Precision Medicine, New York Presbyterian Hospital- Weill Cornell Medicine
Andrea Sboner
Andrea SbonerEnglander Institute for Precision Medicine, New York Presbyterian Hospital- Weill Cornell Medicine
Andrea Sboner
Loredana Puca
Loredana PucaEnglander Institute for Precision Medicine, New York Presbyterian Hospital- Weill Cornell Medicine
Davide PrandiUniversity of Trento
Davide PrandiUniversity of Trento
Mark A RubinEnglander Institute for Precision Medicine, New York Presbyterian Hospital- Weill Cornell Medicine
Mark A Rubin
Mark A RubinEnglander Institute for Precision Medicine, New York Presbyterian Hospital- Weill Cornell Medicine
Mark A Rubin
Howard I ScherMemorial Sloan Kettering Cancer Center
Howard I ScherWeill Cornell Medical College
David S RickmanEnglander Institute for Precision Medicine, New York Presbyterian Hospital- Weill Cornell Medicine
David S Rickman
Francesca DemichelisEnglander Institute for Precision Medicine, New York Presbyterian Hospital- Weill Cornell Medicine
Francesca DemichelisUniversity of Trento
Francesca DemichelisEnglander Institute for Precision Medicine, New York Presbyterian Hospital- Weill Cornell Medicine
Francesca DemichelisUniversity of Trento
David M Nanus
David M NanusEnglander Institute for Precision Medicine, New York Presbyterian Hospital- Weill Cornell Medicine
Scott T Tagawa
Scott T TagawaEnglander Institute for Precision Medicine, New York Presbyterian Hospital- Weill Cornell Medicine
  • 1 - 38

Datasets